Eupraxia Pharmaceuticals News - September 2026
Eupraxia's One-Shot EoE Drug Holds Patients in Remission for a Year — But Can a 14-Patient Trial Justify a $600 Million Bet?
Shares of Eupraxia Pharmaceuticals surged 10.6% to $9.19 after the clinical-stage biotech reported that a single dose of its swallowed steroid capsule kept 64%...
🟢 Eupraxia Pharmaceuticals is trading 10.63% up today after 64% remained in remission at 52 weeks
Eupraxia Pharmaceuticals is trading 10.63% up at $9.19; the clearest catalyst is its September 30 RESOLVE trial report. - In Phase 1b/2a, 9 of 14 patients...
🟢 Eupraxia Pharmaceuticals is trading 5.48% up today amid 52-week clinical remission results
Eupraxia Pharmaceuticals is trading 5.48% higher at $8.76, amid company-reported Phase 1b/2a RESOLVE trial results. - On September 30, 2026, 64% (9 of 14)...
🟢 Eupraxia Pharmaceuticals is trading 13.78% up today in pre-market with no clear company-specific catalyst identified
Eupraxia Pharmaceuticals is trading 13.78% up at $7.35 after no clear company-specific catalyst was identified for September 1, 2026. • No September 1...